Recent Otezla Growth: A Result of the Amgen Acquisition or Benefiting from the Pandemic?

Share this article
Share this article
EXTON, Pa., Feb. 10, 2021 /PRNewswire/ -- Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly acquired psoriasis (PSO) and psoriatic arthritis (PsA) agent, Otezla.
1 In late 2019, the brand was sold to Amgen in order to clear the path for Bristol-Myers Squibb's acquisition of Celgene, considering future regulatory conflicts with BMS' pipeline psoriasis drug, deucravacitinib, an oral TYK2 inhibitor anticipated to be in direct competition with Otezla.
Amgen's purchase of Otezla strengthens the company's long-standing immunology portfolio, including TNF inhibitor, Enbrel, which has been approved in RA for over two decades and also holds a dual PSO/PsA indication. However, according to ongoing feedback collected from US dermatologists and rheumatologists included in Spherix's

Related Keywords

Novarti Cosentyx ,Eli Lilly Taltz ,Bob Bradway ,Kristen Henn ,Eli Lilly ,Bristol Myers Squibb ,Abbvie Skyrizi ,Dermatologic Siliq ,Janssen Tremfya ,Amgen ,Our Services ,Amgen Inc ,Business Development ,Realtime Dynamix ,Ortho Dermatologic Siliq ,Sun Dermatology ,Special Topix ,Multi Specialty Impact ,Realworld Dynamix ,Will Amgen ,Time Dynamix ,World Dynamix ,Global Insights ,Earnings Conference Call ,Myers Squibb Announces Positive Topline Results ,Second Pivotal Phase ,Study Showing Superiority ,Deucravacitinib Compared ,Spherix Global Insights ,பாப் பிராட்வே ,கிறிஸ்டன் கோழி ,எலி லில்லி ,பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் ,மகேன் ,அவர் சேவைகள் ,மகேன் இன்க் ,வணிக வளர்ச்சி ,றேஆழ்டிமே டைனமிக்ஸ் ,சூரியன் தோல் நோய் ,சிறப்பு தோப்பிக்ஷ ,பல சிறப்பு தாக்கம் ,விருப்பம் மகேன் ,நேரம் டைனமிக்ஸ் ,உலகம் டைனமிக்ஸ் ,உலகளாவிய நுண்ணறிவு ,இரண்டாவது முக்கிய கட்டம் ,